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and f Department of Gynecology, University Medical Centre Ljubljana, Ljubljana, SloveniaObjective: To investigate endometrial scratch injury (ESI) as an intervention to improve IVF outcome inwomenwith a history of ET failure.
Design: Systematic review and meta-analysis.
Setting: Not applicable.
Patient(s): Infertile women undergoing IVF after one or more failed ET.
Intervention(s): We included all randomized controlled trials of women undergoing IVF after one or more failed ET, where the interven-
tion group received ESI and controls received placebo or no intervention. Pooled results were expressed as relative risk (RR) with a 95%
conﬁdence interval (95% CI). The review protocol was registered in PROSPERO before starting the data extraction (CRD42017082777).
Main Outcome Measure(s): Live birth rate (LBR), clinical pregnancy rate (PR), multiple PR, miscarriage rate, ectopic pregnancy (EP) PR.
Result(s): Ten studies were included (1,468 participants). The intervention group showed higher LBR (RR 1.38, 95% CI 1.05–1.80) and
clinical PR (RR 1.34, 95% CI 1.07–1.67) in comparison to controls, without difference in terms of multiple PR, miscarriage rate, and EP
PR. Double luteal ESI with pipelle was associated with the greatest effect on LBR (RR 1.54, 95% CI 1.10–2.16) and clinical PR (RR 1.30,
95% CI 1.03–1.65). The ESI was beneﬁcial for patients with two or more previous ET failure, but not for women with a single previous
failed ET. No effect was found in women undergoing frozen-thawed ET cycles.
Conclusion(s): The ESI may improve IVF success in patients with two or more previous ET failures undergoing fresh ET. The ESI timing
and technique seem to play a crucial role in determining its effect on embryo implantation. (Fertil Steril 2018;110:687–702.2018 by
American Society for Reproductive Medicine.)
El resumen está disponible en Español al ﬁnal del artículo.
Key Words: Endometrial scratching, endometrial biopsy, injury timing, infertility, implantation failure
Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertility-
and-sterility/posts/32627-25993I n vitro fertilization is the gold stan-dard treatment for causes of infer-tility, including tubal obstruction,
severe male factor, poor ovarianReceived March 19, 2018; revised April 17, 2018; acc
A.V. has nothing to disclose. A.D.S.S. has nothing to
nothing to disclose. F.S. has nothing to disclose.
to disclose. A.A. has nothing to disclose. G.A. h
Reprint requests: Amerigo Vitagliano,M.D., Departm
necology andObstetrics, University of Padua, Pa
com).
Fertility and Sterility® Vol. 110, No. 4, September 20
Copyright ©2018 American Society for Reproductive
https://doi.org/10.1016/j.fertnstert.2018.04.040
VOL. 110 NO. 4 / SEPTEMBER 2018reserve, and unexplained infertility of
long duration (1, 2). An upward trend
in IVF demand has been recorded in
high income countries (3), with aepted April 26, 2018.
disclose. G.S. has nothing to disclose. G.V. has
M.S.K. has nothing to disclose. M.B. has nothing
as nothing to disclose.
ent ofWomen and Children's Health, Unit of Gy-
dua, Italy (E-mail: amerigovitagliano.md@gmail.
18 0015-0282/$36.00
Medicine, Published by Elsevier Inc.recent survey showing a record of 1 in
20 Japanese babies born through IVF
technique in year 2015 (data provided
by Japan Society of Obstetrics and
Gynecology).
Despite the rapid growth of IVF and
considerable innovations in assisted
reproductive technique (ART) (i.e., im-
plantation genetic screening to assure
transferring euploid embryos) (4, 5),
failure of implantation still occurs in
most IVF cycles (60%–70%) (6–8). It is687
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONassumed that up to two-thirds of implantation failures could
be secondary to defects in endometrial receptivity (9, 10).
Endometrial scratch injury (ESI) is an intervention widely
offered to enhance endometrial receptivity in women with a
history of IVF failure (11). The ESI can be simply achieved
by common biopsy devices (i.e., pipelle, curette), with no
need for analgesia (11, 12). The rationale of performing ESI
is to trigger a local acute inﬂammation, with the release of
cytokines and growth factors that could enhance the
implantation process (13, 14). Nevertheless, since the ﬁrst
study published in 2003 (15), the impact of ESI on IVF
success is still subject of debate (16, 17). Important, there is
still no agreement on the most appropriate timing (day of
the menstrual cycle) and technique (number of performed
endometrial injuries and the optimal device) to be used
(16, 18). In addition, although performing ESI before the
ﬁrst IVF cycle is discouraged at present (17, 19), due to lack
of evidence, it is still unclear after how many failed ET
attempts ESI may be beneﬁcial (16, 17).
The aim of our study was to summarize evidence on ESI
effectiveness in women with a history of one or more failed
ET attempts. In addition, we evaluated the impact of ESI
timing and technique (number of injuries and devices) on
IVF outcome.
MATERIALS AND METHODS
Study Design and Registration
This is a systematic review of all randomized controlled trials
(RCTs) investigating the effects of ESI on IVF outcomes in
women with at least one previous ET failure. Study protocol
was registered in PROSPERO before starting the data extrac-
tion (CRD42017082777). The review was reported following
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines (20).Search Strategy
Electronic databases (Medline, Sciencedirect, Scopus, Em-
base, the Cochrane library, Clinicaltrials.gov, European Union
Clinical Trials Register, and World Health Organization Inter-
national Clinical Trials Registry Platform) were searched from
their inception until November 2017. The key search terms
were as follows: endometrial injury OR endometrial scratch
OR endometrial biopsy OR endometrial sampling OR endome-
trial damage [Mesh/Emtree] AND IVF OR ICSI OR embryo
transfer OR embryo implantation AND failure OR impairment
OR defect.Inclusion Criteria
The inclusion criteria are as follows: studies reported in En-
glish language; randomized controlled trials; infertile women
undergoing a single IVF-ET cycle (with fresh or frozen em-
bryos) after at least one previous ET failure; endometrial
injury during the course of IVF-ET cycle or during the men-
strual cycle preceding IVF-ET; infertile women undergoing
a single IVF-ET cycle (after at least one previous ET failure)
not receiving the intervention (i.e., no intervention or pla-
cebo); primary outcome (live birth rate); secondary outcomes688(clinical pregnancy rate [PR], miscarriage rate [MR], multiple
PR, ectopic pregnancy [EP] PR); and (7) outcomes measures:
live birth rate (per patients [LBR], deﬁned as the delivery of
one or more living infants), clinical PR (per patients, deﬁned
as the visualization of a gestational sac on transvaginal ultra-
sound or other deﬁnitive clinical signs), multiple pregnancies
(per patients, deﬁned as the presence of more than one gesta-
tional sac on transvaginal ultrasound), MR (per clinical preg-
nancy, deﬁned as fetal loss prior to the 20th week of
gestation), ectopic pregnancy (EP) PR (per clinical pregnancy,
deﬁned as a pregnancy that implants outside of the uterus).Study Selection and Data Extraction
Titles and abstracts were independently screened by two au-
thors (A.V., A.A.). The same authors independently assessed
studies for inclusion and checked the reference lists of
retrieved studies. The results of the study selection process
were then matched and any difference was discussed. Two
other authors (G.V., F.S.) extracted data about study features,
populations (number and inclusion criteria), intervention
(tools and timing), cointerventions (i.e., hysteroscopy, antibi-
otics) IVF cycles (ovarian stimulation protocols, embryos
transferred, luteal phase support), and study outcomes. One
author (A.V.) reviewed the entire data extraction process.
When insufﬁcient information was reported in the articles,
we contacted authors (by e-mail) to ask for additional data.Risk of Bias
Two authors (A.V., A.A.) independently assessed the method-
ological quality of included studies by using the Cochrane
Collaboration's tool for bias risk assessment (21). Seven do-
mains related to risk of bias were evaluated: random sequence
generation; allocation concealment (selection bias); blinding
of participants and personnel (performance bias); blinding
of outcome assessors (detection bias); incomplete outcomes
(attrition bias); selective data reporting (reporting bias); other
sources of bias (other bias). Authors' judgments were ex-
pressed as ‘‘low risk’’, ‘‘high risk’’ or ‘‘unclear risk’’ of bias
for each domain. As none of the included studies was blinded
but such factor was unlikely to generate bias, ‘‘performance
bias’’ was considered a low risk for all the included studies.
In addition, ‘‘detection bias’’was evaluated according to qual-
ity of outcomes measures deﬁnition (clear/unclear/inappro-
priate) and possible confounding factors in the detection of
ESI effect (i.e., cointerventions). For the estimation of ‘‘selec-
tive data reporting,’’ we evaluated study protocols, when
available. If not available, studies were judged at unclear
risk of bias. Authors' scores were compared and disagree-
ments were resolved by consensus.Data Analysis
Statistical analysis was performed independently by two au-
thors (A.V., G.S.) using Review Manager Version 5.3 (The Co-
chrane Collaboration, Software Update). The results were
compared and any difference was resolved by discussion with
a third reviewer (A.D.S.S.). All analyses were carried out with
an intention-to-treat approach (number of events per womenVOL. 110 NO. 4 / SEPTEMBER 2018
Fertility and Sterility®randomized), using the random effects model (of DerSimonian
and Laird). Results were expressed using risk ratio (RR) with a
95% conﬁdence interval (95% CI). Signiﬁcance level was set
at P< .05. Heterogeneity was assessed using Higgins I2.
A subgroup analysis was performed to evaluate the
impact of different interventions (timing [follicular vs, luteal],
number [single vs. double], type of device [soft device,
curette]), patients' history of previous ET failures (1 failed
ET, R2 failed ET), type of IVF-ET cycle (fresh, frozen-
thawed), and cointerventions (i.e., hysteroscopy, antibiotics,
oral contraceptive (OC) pill, prednisolone) and on pooled re-
sults. In addition, we performed a sensitivity analysis by seri-
ally excluding each study and different study subgroups
(according to the methodological quality) from the pooled
analysis. We aimed to assess the publication bias for the pri-
mary outcome by using the funnel plot if at least 10 studies
were included in pooled analysis, according to Cochrane
Collaboration (Cochrane Handbook, 10.4.3.1 Recommenda-
tions on testing for funnel plot asymmetry).
Grading of Evidence
The body of evidence was assessed by two authors (A.V., A.A.)
using GRADE (Grading of Recommendations Assessment
Development and Evaluation working group) methodology.
The ﬁnal score was obtained by evaluating the following do-
mains: study design, risk of bias, indirectness, inconsistency,
imprecision, large effect size, plausible confounding, and
publication bias. Dose-response gradient was not evaluated
as intervention was dichotomous.
RESULTS
Study Selection
After titles and abstracts screening, 19 studies were assessed
for eligibility. Eight studies were excluded after the evaluation
of full-text: ﬁve were not RCT (22–26); the Liu et al. (19) study
included patients at their ﬁrst IVF attempt; two additional
trials (14, 27) included unselected women undergoing IVF;
and the Salhepour et al. (28) study was excluded because
endometrial injury was not inﬂicted by using biopsy devices
(but by infusing a saline solution through the cervical
canal). Thus, 10 trials (29–38) were included in the present
systematic review (Supplemental Fig. 1, available online).
Included Studies
The 10 trials included 1,468 participants, of which 733 were
assigned to the intervention group and 735 to the control
group. All studies were open-label (for participants, personnel
and outcomes assessors), except for one trial (38) (double-
blinded). Three studies (33, 34, 36) were multicenter trials.
The study characteristics are reported in Table 1.
Participants. Five studies (30, 32, 34, 37, 38) included women
with at least one previous failed ET attempt. An additional
four trials (29, 33, 35, 36) included women with at least two
previous ET failures, whereas Baum et al. (31) enrolled only
women with three or more previous failed ET cycles. The
mean number of previous failed ET was between two and
three in all studies, except in two (Inal et al. [32], between 1VOL. 110 NO. 4 / SEPTEMBER 2018and 2 cycles; Baum et al. [31], between 8 and 9 cycles).
Information was not provided in the Singh et al. (35) study.
All trial embedded patients with previous good ovarian
response and/or previous failed transfer of good quality
cleavage stage embryos/blastocysts. Reasons for infertility
included male factor, tubal infertility, endometriosis,
unexplained infertility, and anovulation in all studies. Data
were not provided in three articles (29, 34, 35) (Table 1).
Intervention. All patients received ESI during the menstrual
cycle preceding the ET. In ﬁve studies ESI was performed
twice (during the luteal phase [32, 34, 37] or once during
the follicular phase and once during the luteal phase
[30, 31]) and in the remaining studies it was performed once
(29, 35, 36, 38) or during the follicular phase (33). Biopsy
was obtained through ﬂexible biopsy devices—pipelle
(29–32, 34, 36, 37) or Karman's cannula (35), except in the
Shohayaeb and El-Khayat (33) study (by curette). Only in
three trials (31, 34, 38) control patients received placebo
(introduction of a catheter inside cervix without tissue
sampling).
Cointerventions. Patients underwent hysteroscopy (during
the cycle preceding ET) in two studies (30, 33). Doxicicline
(200 mg/d for 7 days) was added in the study by Narvekar
et al. (30). In the study by Singh et al. (35) all women
received antibiotics after ESI (ciproﬂoxacin 500 mg/daily
for 5 days), whereas in another study (32) antibiotics (dose
and drug not described) were administered only to patients
allocated to intervention. In addition, Gibreel et al. (34) used
OC pills for cycle scheduling. Finally, Inal et al. (32)
administered oral prednisolone before ET.
IVF-ET cycles. All women underwent a single homologous
IVF-ICSI cycle with fresh ET, except in two studies (vitriﬁed
warmed ET cycle with 6 mg/d oral E2 valerate preparation
[36] or natural cycle vitriﬁed warmed ET [38]). Pituitary block
was achieved by using the same scheme (GnRH-agonists long
protocol [29, 32, 34, 35]) or various schemes within the same
study population (including GnRH-agonists ultralong/ﬂare
up protocols and GnRH-antagonists ﬂexible scheme
[30, 31, 34, 35]). Ovarian stimulation was started on
days 2–3 of the cycle after ESI with recombinant FSH
(29, 30, 35, 37) or recombinant FSH/hMG, mainly adapting
dose of gonadotropins (150–375 IU daily) on patients'
characteristics (in one study (29) patients received a ﬁxed
daily dose of 225 IU FSH). Ovulation was triggered with
5,000–10.000 IU of urinary hCG or 250 mg of recombinant
hCG when at least two/three follicles exceeded the mean
diameter of 17–18 mm. Oocyte retrieval was performed 34–
37 hours after ovulation induction and oocytes were
fertilized by IVF/intracytoplasmic sperm injection (ICSI)
(except in the study by Inal et al. (32) using only ICSI).
Subsequently, a variable number (%3) good quality
cleavage stage embryos or blastocysts were transferred
(only cleavage stage embryos in six studies (29–33, 36);
cleavage stage embryos or blastocysts in the remaining
studies (34, 35, 37, 38). Luteal phase support was achieved
by administering vaginal P (200–800 mg/d) alone or in
combination with IM P (25 mg/d or 100 mg twice a week)
from the day of oocyte pick-up. Inal et al. (32) administered689
TABLE 1
General features of the studies.
Author and year
Study design, country and
time of realization
Participants and main
inclusion criteria (n)
Ovarian stimulation (drugs
and techniques) Intervention group Control group Outcomes
Karimzadeh et al. 2009
(29)
Single center RCT
Iran
nr
115 patients undergoing
IVF-ICSI
2–6 failed IVF-ET cycles
withR10 high-grade
embryos transferred
Mean number of failed
cycles:
Group A: 2.52  1.42
Group B: 2.18  0.54
No previous poor ovarian
response (deﬁned as
day 3 FSH>10 IU⁄mL or
<4 follicles at hCG)
Age 20–40 years
No history of blood disease
No uterine malformation,
endometriomas, and
hydrosalpinx
GnRH-ag long protocol
(busereline 0.25–
0.5 mg/d)
Recombinant FSH 225 IU
from day 2
Urinary hCG (10,000 IU) at
follicle size 18 mm
(R2)
Oocyte retrieval 34–36 h
after hCG
2/3 day 2/3 embryos
transferred
Luteal phase support with
vaginal P (800 mg/d)
Single ESI on days 21–26
Pipelle
Group A (n¼ 58women; 4
lost to follow-up; 6 did
not undergo ET)
Cointerventions:
none
No intervention
Group B (n¼ 57 women; 5
lost to follow-up; 7 did
not undergo ET)
Cointerventions:
none
Clinical PR
Narvekar et al. 2010 (30) Single center RCT
India
May 2007 to July 2008
100 patients undergoing
IVF-ICSI
R1 failed IVF-ET cycles
withR4 high-grade
embryos transferred
Mean number of failed
cycles:
Group A: 2.3  0.52
Group B: 2.5  0.7
Previous good ovarian
response
Age%37 years
No history of endometrial
tuberculosis and
Asherman syndrome
No submucous ﬁbroids/
ﬁbroids distorting
uterine cavity
No hydrosalpinx
GnRH-ag long/short
(leuprorelin 0.2–
0.5 mg/d) or GnRH-ant
(ganirelix 0.25 mg)
ﬂexible protocol
Recombinant FSH 150–
250 IU from day 3
urinary hCG (5.000 IU)
at follicle size 18 mm
(R3)
Oocyte retrieval 35 h after
hCG
%4 day 3 high-grade
embryos transferred
Luteal phase support with
vaginal P (600 mg/d)
Double ESI on days 7–10
and 24–25
Pipelle
Group A (n¼ 49women; 1
received P-ESI once)
Cointerventions:
hysteroscopy, antibiotics
No intervention
Group B (n ¼ 51 women)
Cointerventions:
hysteroscopy, antibiotics
Clinical PR
Live birth rate
Miscarriage rate
Multiple PR
Baum et al. 2012 (31) Single center RCT
Israel
July 2006 to June 2009
36 patients undergoing
IVF-ICSI
R3 failed IVF- ET cycles
Mean number of failed
cycles:
GnRH-ag long/short or
GnRH-ant protocol
Urinary hCG (5,000 UI)) at
follicle size of 18 mm
(>2)
Double ESI on days 9–12
and 21–24
Pipelle
Group A (n ¼ 18 patients;
1 did not receive COS;
Placebo
(cervical pipelle, without
biopsy)
Group B (n¼ 18 patients; 1
not receive COS; 1 did
Clinical PR
Live birth rate
Miscarriage rate
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TABLE 1
Continued.
Author and year
Study design, country and
time of realization
Participants and main
inclusion criteria (n)
Ovarian stimulation (drugs
and techniques) Intervention group Control group Outcomes
Group A: 8.8  4.6
Group B: 8.5  3.5
Previous good ovarian
response
Age 18–41 years
No uterine malformations,
endometriomas, and
hydrosalpinx
Variable number of day 3
embryos transferred
Luteal phase support not
described
1 did not undergo ET)
Cointerventions:
none
not undergo ET)
Cointerventions:
none
Inal et al. 2012 (32) Single center RCT
Turkey
January 2008 to March
2009
100 patients undergoing
ICSI
R1 failed IVF-ET cycles
Mean number of failed
cycles:
Group A: 1.3  0.57
Group B: 1.44  0.6
Previous good ovarian
response
No hydrosalpinx,
thrombophilia, and
submucous myoma
GnRH-ag long protocol
(leuprorelix 1 mg/d)
Recombinant FSH or hMG
(dose according to
patient characteristics)
Urinary hCG (10,000 IU) at
follicle size of 18–20 (1)
or 17 mm (2)
Oocyte retrieval 35–37 h
after hCG
%3 day 3 high-grade
embryos transferred
Luteal phase support with
vaginal P (600 mg/d),
IM P (25 mg/d), oral
prednisolone (16 mg/
d for 5 d) and
transdermal E2 100 mg
(alternate days)
Double ESI during luteal
phase (7-day interval)
Pipelle
Group A (n ¼ 50 patients)
Cointerventions:
antibiotics, prednisolone
No intervention
Group B (n ¼ 50 patients)
Cointerventions:
prednisolone
Clinical PR
Live birth rate
Miscarriage rate
Shohayeb and El-Khayat
2012 (33)
Multicenter RCT
Egypt, Saudi Arabia
nr
210 patients undergoing
IVF-ICSI
R2 failed IVF- ET cycles
Mean number of failed
cycles:
Group A: 2.9  1.0
Group B: 2.84  1.04
Previous transfers of good
quality embryos
Endometrial thickness
<5 mm on day 4
Age <39 years
No submucous myoma,
endometrial polyp,
intrauterine synechiae,
or uterine
malformation
GnRH-ag long protocol
(triptorelin 1 mg/dy) or
GnRH-ant protocol
(centrorelix 0.25 mg/d)
Recombinant FSH or hMG
(dose according to
patient characteristics)
Ovulation induction at
follicle size of 18 mm
(R3)
Oocyte retrieval 36 h after
hCG
Day 3 embryos transferred
(variable number)
Vaginal P 400 mg for luteal
phase support
Single ESI on days 4–7
Curette
Group A (n¼ 105 patients;
2 lost because of low
response; 3 lost
because of low embryo
quality)
Cointervention:
hysteroscopy
No intervention
Group B (n¼ 105 patients;
3 lost because of low
response; 2 lost
because of low embryo
quality)
Cointervention:
hysteroscopy
Clinical PR
Live birth rate
Miscarriage rate
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TABLE 1
Continued.
Author and year
Study design, country and
time of realization
Participants and main
inclusion criteria (n)
Ovarian stimulation (drugs
and techniques) Intervention group Control group Outcomes
Gibreel et al. 2015 (34)
[NCT01245309]b
Multicenter RCT
Egypt; Belgium
nr
387 patients undergoing
IVF/ICSI
R1 previous failed IVF-ET
Age <40 years
Number of failed cycles
among groups:
Group A: (n¼ 128, 1 cycle;
n ¼ 64,R2 cycles)
Group B: (n¼ 124, 1 cycle;
n ¼ 70,R2 cycles)
No previous poor ovarian
response.
No endocrine disorders
No uterine abnormalities
and hydrosalpinx
No recent endometrial
curettage (past
3 months).
GnRH-ag long protocol
Gonadotropins and hCG
not described
2 day 3 or 1 day 5 embryo
transferred
Luteal phase support with
micronized P twice
Double ESI on days 21 and
23–24
Pipelle
Group A (n¼ 193 patients;
178 received ESI twice;
15 underwent
hysteroscopy and ESI
once; 3 lost follow-up)
Cointervention:
contraceptive pill
Placebo
(introduction of a sound
through cervix
stopping before
internal os)
Group B (n¼ 194 patients;
182 received placebo
twice; 12 underwent
hysteroscopy; 2 lost
follow-up)
Cointervention:
contraceptive pill
Clinical PR
Live birth rate
Multiple PR
Miscarriage rate
Singh et al. 2015 (35) Single center RCT
India
April 2013 to July 2014
60 patients undergoing
IVF-ICSI
R2 previous failed IVF
cycles
Number of failed cycles
among groups: nr
Age <35 years
AFC >8, AMH 2–6 ng/mL,
FSH <8 m IU/mL
No uterine manipulation
within past 3 months
No severe endometriosis
No abnormal uterine cavity
No diabetes mellitus,
hypertension. and
autoimmune diseases
GnRH-ag long protocol
(leuprorelix 1 mg/d)
Recombinant FSH 150–
375 IU/d
Recombinant hCG
(250 mg) at follicle size
>18 mm (2–3)
Oocyte retrieval 34–36 h
after hCG
Day 2–5 embryos
transferred (variable
number)
Luteal phase support with
vaginal P (300 mg/d) or
IM P (100 mg/d)
Single ESI on days 14–21
Karman's cannula
Group A (n ¼ 30 patients)
Cointervention:
antibiotics
No intervention
Group B (n ¼ 30 patients)
Cointervention:
antibiotics
Clinical PR
Live birth rate
Miscarriage rate
Shahrokh-Tehraninejad
et al. 2016 (36)
[201311065181N12R]b
Multicenter RCT
Iran, USA
January 2013 to December
2014
120 patients undergoing
IVF-ICSI (frozen)
R2 previous failed IVF
cycles
Mean number of failed
cycles:
Group A: 2.3  0.5
Group B: 2.8  0.7
Age <40 years, BMI%30
GnRH-ant (buserelin
1.05 mg/d) from luteal
phase
Oral E2 valerate (6 mg/d)
from day 3 of next cycle
Vaginal P (400 mg/d) at
8 mm endometrial
thickness
Single ESI on day 21
Pipelle
Group A (n ¼ 60 patients)
Cointervention:
none
No intervention
Group B
(n ¼ 60 patients)
Cointervention:
none
Clinical PR
Live birth rate
Miscarriage rate
Ectopic PR
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TABLE 1
Continued.
Author and year
Study design, country and
time of realization
Participants and main
inclusion criteria (n)
Ovarian stimulation (drugs
and techniques) Intervention group Control group Outcomes
R4 grade 1 embryos
available
Normal uterine cavity
No submucosal,
intramural, or large
(>5 cm) subserosal
myoma
No endometriomaR3 cm,
hydrosalpinx,
endometrial
tuberculosis, active
vaginal or cervical
infection, diabetes, and
systemic lupus
erythematosus
Day 3 embryos transferred
(variable number)
Mak et al. 2017 (38)
[ChiCTRTRC-
12002389]b
Single center RCT
Hong Kong, People's
Republic of China
March 2013 to April 2016
229 patients undergoing
IVF-ICSI (frozen)
R1 previous failed ET
cycles
Normal ovulatory cycles
No uterine anomaly or
pathology
such as endometrial
polyps, endometriomas
>4 cm,
or hydrosalpinx
Tubal factor
Male factor infertility
Endometriosis
Unexplained infertility
Natural cycle
Day 2-6 embryos
transferred (1 or 2)
Luteal phase support not
administered
Single ESI on day LH þ 6/8
Pipelle
Group A (n¼ 115 patients;
15 did not receive ESI, 7
did not undergo ET)
Cointervention:
none
Placebo
(sterile cotton wool stick
inserted in the cervical
os)
Group B
(n ¼ 114 patients; 10 did
not receive ESI, 11 did
not undergo ET)
Cointervention:
none
Clinical PR
Ongoing
pregnancy/live
birth ratea
Miscarriage rate
Multiple PR
Aleyamma et al 2017 (37)
[CTRI/2013/003564]b
Single center RCT
India
April 2008 to April 2015
111 patients undergoing
IVF-ICSI
R1 previous failed IVF
cycle withR2 good
quality embryos
transferred
Mean number of failed
cycles:
Group A: 2.38  0.63
Group B: 2.46  0.90
No previous poor ovarian
response (<3 oocytes)
GnRH-ag long/ultra-long/
ﬂare-up protocol
(leuprorelin 0.5 mg/d/
3.75 mg depot) or
GnRH-ant ﬂexible
protocol (ganirelix
0.25 mg/d)
Recombinant FSH 150–
300 IU
Urinary hCG (5,000 IU) at
follicle size >17 mm
(R3)
Double ESI (within
48 hours) in luteal
phase
Pipelle
Group A (n ¼ 55 patients:
11 drop-out [2 patients
refused; 7 before
oocyte retrieval
[functional cysts, poor
response, low E2 on
day of trigger, fever on
day of trigger]; 2 after
No intervention
Group B
(n ¼ 56 patients: 9 drop-
out [3 lost before
oocyte retrieval [poor
response], 6 after
oocyte retrieval
[elective embryo
cryopreservation, no
M2 oocytes,
fertilization failure,
sudden panic attack])
Clinical PR
Live birth rate
Multiple PR
Miscarriage rate
Vitagliano. Endometrial injury for IVF failures. Fertil Steril 2018.
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ORIGINAL ARTICLE: ASSISTED REPRODUCTIONalso oral prednisolone (16 mg/d for 5 days after) and trans-
dermal E2 (100 mg on alternate days). One study (31) did
not report details about embryos (stage at ET) and luteal phase
support. The use of preimplantation genetic testing was not
reported in any study.Assessment of the Risk of Study Bias
Selection bias
 Most studies used adequate methods of random sequence
generation (computer randomization or random tables),
except in two (29, 36; high risk of bias). Allocation
concealment was not described in ﬁve trials (29, 31, 32,
35, 36) (unclear risk of bias), whereas the remaining
studies used opaque sealed envelopes (low risk of bias).Performance bias
 Because the evaluated outcomes were unlikely to be inﬂu-
enced by the lack of blinding, all studies were judged at low
risk of bias.Detection bias
 Five studies (30, 32–35) were considered at unclear risk of
bias due to the presence of cointerventions with
uncertain inﬂuence on the outcomes evaluated (i.e.,
hysteroscopy, antibiotics, prednisone).Attrition bias
 All studies were at low risk of bias, except the one by Singh
et al. (35; high risk of bias due to attrition between data out-
comes) and the one by Mak et al. (38; unclear risk of bias as
live births and ongoing pregnancies were not reported
separately).Reporting bias
 Due to absence of recorded protocol, all studies but three
(34, 36, 37) were judged at unclear risk of selective data
reporting.Other bias
 Three studies were judged at low risk of other bias
(30, 37, 38). Other studies were at unclear/high risk of
bias due to lack of description of population
characteristics (i.e., IVF cycle techniques) or due to
absence of power analysis/intention to treat analysis
(Supplemental Fig. 2, available online).Synthesis of Results
Primary outcome. A total of 1,124 participants (n ¼ 560 in
the intervention group and n ¼ 564 in the control group)
from eight studies (30–37) were evaluated. A signiﬁcantly
higher pooled LBR was found in patients receiving ESI (RRVOL. 110 NO. 4 / SEPTEMBER 2018
Fertility and Sterility®1.38, 95% CI 1.05–1.80, I2¼ 26%, P¼ .02) compared with the
control group (Fig. 1A).
Secondary outcomes. The analysis of 1,468 patients (from
all the 10 studies [29–37]) found higher clinical PR (RR
1.34, 95% CI 1.07–1.67, I2 ¼ 38%, P ¼ .01) in patients
receiving ESI (Fig. 2A). There was with no difference in
terms of multiple PR (RR 1.09, 95% CI 0.64–1.85, I2 ¼ 0,
P ¼ .76), MR (RR 0.97, 95% CI 0.65–1.47, I2 ¼ 0, P ¼ .90),
and EP PR (RR 3.00, 95% CI 0.12–72.20, I2 ¼ not
applicable, P ¼ .50) compared with the control group.Subgroup analysis
Subgroup analysis was performed for the outcomes LBR and
clinical PR (I2¼ 0 for MR andmultiple PR; I2¼ not applicable
for EP PR). This was also done for splitting patients according
to type of intervention (ESI number, timing, and device), his-
tory of previous failed IVF-ET attempts (1,R2), type of ET cy-
cle (fresh vs. frozen), and presence of cointerventions
(hysteroscopy, antibiotics, OC pill).
Type of intervention. The maximum effect of intervention
was correlated with double luteal ESI (performed with a pi-
pelle), in terms of LBR (RR 1.54, 95% CI 1.10–2.16, I2 ¼ 0,
P ¼ .01) and clinical PR (RR 1.30, 95% CI 1.03–1.65,
I2 ¼ 18%, P ¼ .03). Data from one study (33) showed advan-
tage from single follicular ESI (performed by curette) in terms
of LBR (RR 2.36, 95% CI 1.16–4.81, I2 ¼ not applicable,
P ¼ .03) and clinical PR (RR 1.78, 95% CI 1.07–1.96,
I2 ¼ not applicable, P ¼ .03). No beneﬁt was observed from
single luteal ESI and double follicular-luteal ESI (both ob-
tained through ﬂexible devices), in terms of LBR and clinical
PR (P ¼ not signiﬁcant [NS]) (Figs. 1B and 2B).
History of implantation failure. The ESI was associated with
higher LBR (RR 1.64, 95% CI 1.21–2.21, I2 ¼ 0, P ¼ .001) and
clinical PR (RR 1.57, 95% CI 1.22–2.03, I2 ¼ 6%, P ¼ .0005)
only inwomenwith two ormore previous failed ET. Differently,
the pooled analysis of studies on women with a single previous
ET failure did not show any difference with controls in terms of
clinical PR and LBR (P ¼ NS) (Figs. 1C and 2C).
Type of ET cycle. We found a signiﬁcant effect of ESI on LBR
(RR 1.44, 95% CI 1.05–1.97, I2 ¼ 34%, P ¼ .002) and clinical
PR (RR 1.49, 95% CI 1.12–1.99, I2 ¼ 41%, P ¼ .006) in fresh
ET cycles. Differently, the two studies (36, 38) on frozen-
thawed ET cycles did not ﬁnd any advantage from ESI
(P ¼ NS).
Cointerventions. Studies in which ESI was associated with
cointerventions (30, 32–35, 37) showed signiﬁcantly higher
clinical PR (RR 1.49, 95% CI 1.14–1.95, I2 ¼ 32%, P ¼ .003)
and LBR (RR 1.53, 95% CI 1.10–2.12, I2 ¼ 33%, P ¼ .01) in
comparison with other studies (P ¼ NS). The major effect of
ESI was observed in studies in which hysteroscopy was
performed before ESI (30, 33) (clinical PR: RR 1.93, 95% CI
1.26–2.97, I2 ¼ 0, P ¼ .003; LBR: RR 2.07, 95% CI 1.26–
3.42, I2 ¼ 0, P ¼ .004), with/without the addition of
antibiotic therapy. No beneﬁt from ESI (clinical PR and
LBR, P ¼ NS) was found in patients receiving OCs (data
from a single study [34]).VOL. 110 NO. 4 / SEPTEMBER 2018Sensitivity analysis
The exclusion of the study by Shohayeb et al. (33) from pooled
analysis produced statistical changes to LBR (RR 1.29, 95% CI
0.98–1.70, I2¼ 20%, P¼ .07), but not to clinical PR (RR 1.29,
95% CI 1.02–1.63, I2 ¼ 37%, P ¼ .03). Sensitivity analysis
based on study quality (with the exclusion of 2 studies [32,
35] at high/unclear risk of bias in 4 domains) did not provide
any substantial change to clinical PR (RR 1.30, 95% CI 1.01–
1.67, I2 ¼ 43%, P¼ .04), but reduced the effect of ESI on LBR
(RR 1.34, 95% CI 1.01–1.79, I2 ¼ 26%, P ¼ .05). Differently,
no changes in pooled multiple PR and MR (not feasible for
the outcome EP PR due to few data) resulted from sensitivity
analysis.Pain and complications
Two studies (29, 31) reported no complications associated
with ESI. The remaining studies did not report any
information. Similarly, no data was available about
patients' discomfort, as well as about long-term complica-
tions associated with ESI.Overall Quality of Evidence
The quality of evidence was rated as low for LBR, clinical PR,
MR, and multiple PR, very low for EP PR. We judged the cu-
mulative risk of bias as serious/very serious due to methodo-
logical ﬂaws of most studies (5 of 10 studies were at unclear/
high risk of bias in at least 3 domains). In addition, the body of
evidence was limited by serious imprecision, as well as by
serious/very serious indirectness (Table 2). Publication bias
was strongly suspected (Funnel plot was not built as <10
studies were evaluated for the primary outcome).
DISCUSSION
Main Findings
The present meta-analysis included 1,468 participants (from
10 RCTs [29–38]) undergoing a single IVF-ET cycle after
one or more previous failed attempts. Patients allocated to
intervention received ESI once or twice during the cycle pre-
ceding ovarian stimulation, whereas controls received no
intervention or placebo.
The intervention group showed signiﬁcantly higher LBR
(RR 1.38, 95% CI 1.05–1.80, P ¼ .02; GRADE score low) and
clinical PR (RR 1.34, 95% CI 1.07–1.67, P¼ .01; GRADE score
low) in comparison with controls, without difference in terms
of multiple PR, MR, and EP PR (P ¼ NS; GRADE score low/
very low). Interestingly, subgroup analysis showed that dou-
ble luteal ESI with pipelle (data from 3 studies) was associated
with the maximum effect on LBR (RR 1.54, 95% CI 1.10–2.16,
P¼ .01) and clinical PR (RR 1.30, 95% CI 1.03–1.65, P¼ .03),
with minimal inconsistency (I2 ¼ 0 for LBR and I2 ¼ 18% for
clinical PR). In addition, single follicular ESI through Novak
curette (data from 1 study) showed also a beneﬁt on LBR
(RR 2.36, 95% CI 1.16–4.81, P ¼ .03) and clinical PR (RR
1.78, 95% CI 1.07–1.96, P ¼ .03). No effects of single luteal
ESI (by pipelle) and double follicular-luteal ESI (by pipelle
or Karman's cannula) were observed (P ¼ NS).695
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TABLE 2
Evidence proﬁle: endometrial injury compared with no intervention in patients with one or more previous embryo transfer failure.
Characteristic
Anticipated absolute effects (95% CI)
Relative effect
(95% CI)
No. of participants
(studies)
Certainty of the
evidence (GRADE)
Risk with no
intervention
Risk with
endometrial injury
Ongoing pregnancy/live
birth rate
24 per 100 34 per 100 (26–44) RR 1.38 (1.05–1.80) 1,124 (8 RCTs) Lowa,b,c
Clinical pregnancy rate 28 per 100 37 per 100 (30–46) RR 1.34 (1.07–1.67) 1468 (10 RCTs) Lowa,b,c
Miscarriage rate 17 per 100 16 per 100 (11–24) RR 0.97 (0.65–1.47) 440 (9 RCTs) Lowa,b,c
Multiple pregnancy rate 6 per 100 7 per 100 (4–11) RR 1.09 (0.64–1.85) 827 (4 RCTs) Lowb,c
Ectopic pregnancy rate 0 per 100 0 per 100 (0–0) RR 3.00 (0.12–72.20) 120 (1 RCT) Very lowd,e
Note: CI ¼ conﬁdence interval; GRADE ¼ Grading of Recommendations Assessment Development and Evaluation; RR ¼ relative risk; RCT ¼ randomized controlled trial.
a Majority of studies at high/unclear risk of bias in four or more domains.
b High heterogeneity among study populations, type of intervention, and cointerventions.
c The number of participants is insufﬁcient to detect a precise estimate of the effect.
d Study at unclear/high risk of bias in three domains.
e 120 participants included (with one, an event occurred).
Vitagliano. Endometrial injury for IVF failures. Fertil Steril 2018.
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONThe ESI was beneﬁcial only for patients with two or more
previous ET failure (LBR: RR 1.64, 95% CI 1.21–2.21, I2 ¼ 0,
P ¼ .001; clinical PR: RR 1.57, 95% CI 1.22–2.03, I2 ¼ 6%,
P¼ .0005), but not for women with single previous ET failure
(P ¼ NS). In addition, ESI improved IVF success only in
women undergoing fresh ET cycles (LBR: RR 1.44, 95% CI
1.05–1.97, I2 ¼ 34%, P ¼ .002; clinical PR: RR 1.49, 95% CI
1.12–1.99, I2¼ 41%, P¼ .006), without any effect on women
undergoing frozen-thawed ET cycles (P ¼ NS).
Notably, the ﬁnal effect of ESI was potentially inﬂuenced
by the administration of cointerventions (on clinical PR and
LBR: positive effect of hysteroscopy with/without antibiotic
therapy and negative effect of OCs). No complications associ-
ated with ESI were found.Implications
Despite thegrowing scientiﬁc advances in reproductivemedicine
(39–41), implantation remains the rate-limiting step for the suc-
cess of ART (35, 37). Successful implantation entails a complex
series of events, culminating in the incorporation of blastocyst
in endometrial stroma. For this process to be accomplished,
three prerequisite factors are needed: an embryo with
implantation competency, a receptive endometrium, and
synchrony between embryo and endometrium (42, 43).
It has been hypothesized that performing ESI during
the cycle before ovarian stimulationmay enhance endometrial
receptivity and promote embryo-endometrium synchroniza-
tion (12, 37). Speciﬁcally, acute endometrial inﬂammation
may promote embryo-uterine crosstalk through the
local release of cytokines, growth factors, and adhesion
molecules (44, 45). In addition, subsequent endometrial
healing may delay endometrial maturation (minimizing the
effect of ovarian stimulation), thereby facilitating the
synchronization between endometrium and embryo (34, 37).
It is reasonable to assume that the degree of ESI (by gentle
devices or curette), the number of ESI (1 or 2) and the time
elapsing between ESI and the ET may play a crucial role in
determining the impact of this intervention on implantation.
Accordingly, our study provides ﬁrst evidence of the varying698scenarios resulting from the combination of different ESI
techniques (including devices and number of injuries) and
timing.
We insightfully found that, when achieved by ﬂexible bi-
opsy devices, ESI was effective in improving LBR and clinical
PR only if performed twice during the luteal phase (but not
once during the luteal phase or twice during follicular and
luteal phase). In addition, results from a single study (33)
showed a positive effect from single follicular ESI achieved
by curette.
Even if these results are intriguing, caution is needed in
drawing any ﬁrm conclusion about the most effective tech-
nique for ESI. The study by Shohayeb et al. (33) was poten-
tially affected by different sources of bias (3 domains
judged at unclear risk of bias), including a small number of
patients (n¼ 210) and events (n¼ 42 live births). In addition,
no study compared the effect of types of intervention on IVF
success, limiting any assumption regarding the most efﬁcient
number (single or double), timing (follicular or luteal), and de-
vice (soft device or curette) for performing ESI.
Furthermore, we found a positive effect of ESI (in terms of
clinical PR and LBR) only in patients with two or more previ-
ous failed ET. These results were in agreement with the ﬁnd-
ings of the most recent systematic review (18) on the topic
(although more consistent in our study, after the inclusion
of data from 4 additional RCTs [35–38]). In addition, we
newly demonstrated that ESI was ineffective in women with
a single previous failed ET (even if performed twice by
pipelle during the luteal phase). Thus, despite the evidence,
which is limited by few data (n ¼ 386 patients), currently
there is no rationale to offer ESI with the purpose to
overcome a single ET failure.
In addition, we observed a consistent advantage from ESI
only in patients undergoing fresh ET cycles. Differently, no
effect was found (in LBR and clinical PR) in women undergo-
ing frozen-thawed ET cycles. The results by Sharokh-Tehrani-
nejad et al. (36) and by Mak et al. (38) were in line with the
ﬁndings of a recent nonrandomized study (46) (including pa-
tients with %3 previous failed ET). In this respect, we may
speculate that frozen-thawed ET cycles (rather than freshVOL. 110 NO. 4 / SEPTEMBER 2018
Fertility and Sterility®cycles) may provide a more accurate endometrial preparation,
reducing the risk of premature endometrial maturation
(mainly induced by ovarian stimulation drugs) (47, 48).
Thus, the positive impact of ESI on embryo-endometrium
synchronization may be irrelevant in this particular case.
Therefore, we should stress that these two studies (36, 38)
evaluated frozen-thawed ET cycles with supernumerary
(vitriﬁed) embryos. Accordingly, the lower quality of residual
embryos transferred may have affected any positive impact of
ESI on IVF success. In addition, both studies (36, 38) included
women with a history of failed fresh and/or frozen-thawed ET
cycles. This may represent an additional source of bias in the
estimation of the beneﬁts of ESI in women undergoing a
frozen-thawed ET cycle after one or more ET failures.
We also pointed out the presence of cointerventions in
most studies (30, 32–35) (i.e., hysteroscopy, antibiotic
therapy, OC treatment, and oral prednisolone) that may
potentially interfere with the effects of ESI on implantation.
Hysteroscopy was offered to all patients during the cycle
preceding IVF in two studies (30, 33). Interestingly, both
studies demonstrated a great advantage from ESI on IVF
success (clinical PR: RR 1.93, 95% CI 1.26–2.97, I2 ¼ 0,
P ¼ .003; LBR: RR 2.07, 95% CI 1.26–3.42, I2 ¼ 0,
P ¼ .004). Nevertheless, according to the results of a recent
systematic review (49), hysteroscopy itself may improve IVF
success (mainly by removing the antiadhesive glycoprotein
molecules on the endometrial surface and by disrupting
cervical adhesions). In addition, the occasional scratching of
the hysteroscope on the endometrial surface may inﬂict
various degrees of endometrial damage (50, 51), which may
add to the damage generated by ESI. Therefore, even if
hysteroscopy was performed in both intervention and
control groups, its effects may vary from case to case and
its impact on pooled results was not measurable.
Antibiotic therapy was administered in three studies
(30, 32, 35) (only in the intervention group in the study by
Inal et al. [32]). It is a recent acquisition that subclinical
chronic endometritis may often occur in patients affected
by infertility, especially in case of previous IVF failures
(52, 53). Antibiotic therapy also can restore normal
endometrial histology and improve IVF success in these
patients (54, 55). Because none of the study investigated
chronic endometritis, the impact of antibiotics on IVF
outcome could not be quantiﬁed.
In addition, OCs were administered in the cycle before IVF
in a single study (34). Interestingly, ESI (performed twice with
pipelle during the luteal phase) did not provide any effect on
LBR and clinical PR in such patients, suggesting a possible
interference with OC therapy. We may hypothesize that OCs
may preclude the mechanism of ‘‘delayed menstruation’’ pro-
moted by ESI. This may foreclose the synchronization be-
tween endometrium and embryo, thereby abolishing the
positive effect of ESI on implantation. However, a previous
RCT (14) on unselected women undergoing IVF (including
some women with previous ET failures) observed different re-
sults (positive effect from ESI on LBR). Thus, more evidence is
still needed to conﬁrm a potential interaction between OCs
and ESI effects on implantation.VOL. 110 NO. 4 / SEPTEMBER 2018Finally, in the study by Inal et al. (32), all patients received
oral prednisolone (16 mg/d for 5 days after oocyte retrieval).
Due to its well-known immunomodulating action (56, 57), a
potential interference of prednisolone with ESI effect
cannot be excluded. Nevertheless, Inal et al. (32) reported
more clinical PR and LBR in the intervention group,
apparently contradicting such hypothesis.Points of Strength and Limitations
The present systematic review is the largest and most compre-
hensive (of published and unpublished data) investigating the
impact of ESI on IVF-ET success in women with history of im-
plantation failure. We provide the ﬁrst evidence on the inﬂu-
ence of different ESI timing (follicular, luteal), number (single,
double), and devices for ESI (soft device, curette) on IVF
outcome. We also evaluated the impact of ESI on different
subgroups of patients (i.e., with history of single or repeated
ET failure) and different types of IVF-ET cycles (fresh,
frozen-thawed).
We excluded data from studies including women with
unselected number of previous ETs (i.e., including also women
at their ﬁrst IVF attempt) to avoid additional bias due to pa-
tients' inconsistency at the time of randomization. However,
the considerable heterogeneity between original studies in pa-
tients' characteristics, tools for the identiﬁcation of uterine
diseases, techniques for IVF-ET cycles, type of embryos trans-
ferred (cleavage stage embryos vs. blastocysts), and cointer-
ventions represent the main point of weakness of this
present study. In addition, the lack of genetic testing of pre-
implantation embryos and of search for chronic endometritis
did not rule out embryo aneuploidy and endometrial inﬂam-
mation as causes for implantation failure. In addition, the low
number of included studies evaluating speciﬁc outcomes (i.e.,
LBR available for 1,124 of 1,468 patients) and subgroups (i.e.,
ESI in follicular phase, single ESI, and frozen-thawed ET cy-
cles) requires a cautious interpretation of our ﬁndings due to
possibility of type II error. Finally, as trials involved a variable
number of embryos transferred, we did not perform an aggre-
gate analysis for the outcome implantation rate to avoid unit
of randomization error. For all such reasons, the overall qual-
ity of evidence was rated as low/very low.
CONCLUSIONS
In conclusion, we found low quality evidence that ESI may
improve LBR and clinical PR in women with two or more pre-
vious failed ET undergoing fresh IVF-ET cycles. Therefore, ESI
did not increase IVF success in women with a history of a sin-
gle failed ET (independently from the timing and device used),
nor in patients undergoing frozen-thawed ET.
We found no evidence of a negative impact of ESI on
multiple PR, MR, and EP PR. Similarly, no complications
have been associated with the procedure.
Given the limitations of available studies (including
serious imprecision and indirectness), we recommend further
well-designed RCTs on ESI, focusing on patients with homo-
geneous characteristics (i.e., ovarian reserve, cause of infer-
tility, ovarian stimulation protocols, stage and number of699
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONembryos transferred, type of luteal phase support, and num-
ber of failed ET) and avoiding bias due to cointerventions
(hysteroscopy, antibiotic therapy, and OC) and due to the
lack of preimplantation genetic testing. In addition, as all
the studies performed ESI during the menstrual cycle preced-
ing IVF-ET (during the follicular or the luteal phase), future
studies evaluating the impact of ESI during the course of
IVF-ET cycle (i.e., during ovarian stimulation) are warranted.
Finally, future RCTs comparing types of intervention are still
needed to establish the most effective number (single or dou-
ble), timing (follicular or luteal), and device (soft device or
curette) for performing ESI.
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ORIGINAL ARTICLE: ASSISTED REPRODUCTIONLesion por rascado endometrial para mujeres con uno o mas fracasos previos en transferencias de embriones: Una revision sistematica y
meta-analisis de los estudios controlados aleatorizados
Objetivo: Investigar la lesion por rascado endometrial (ESI) como una intervencion para mejorar el resultado de FIV en mujeres con
historia de fracaso en transferencias de embriones.
Dise~no: Revision sistematica y meta-analisis.
Entorno: No aplica.
Paciente (s): Mujeres esteriles sometidas a FIV despues de uno o mas fracasos previos en transferencias de embriones.
Intervencion (s): Se incluyen todos los estudios controlados aleatorizados demujeres sometidas a FIV despues de uno omas fracasos en
transferencias de embriones, donde al grupo con intervencion se le practico ESI y los controles recibieron placebo o ninguna inter-
vencion. Los resultados agrupados se expresaron como riesgo relativo (RR) con un intervalo de conﬁanza del 95% (95% CI). El protocolo
de revision fue registrado en PROSPERO antes de iniciar la extraccion de los datos (CRD42017082777).
Principales variables de resultado: Tasa de nacido vivo (LBR), tasa de gestacion clínica (PR), tasa de gestacion multiple, tasa de aborto
y tasa de gestacion ectopica (EP) PR.
Resultado (s): Se incluyeron 10 estudios (1468 participantes). El grupo con intervencion mostro una LBR (RR 1.38, 95% CI 1.05-1.8) y
una PR (RR 1.34, 95% CI 1.07-1.67) mas elevadas comparado con los controles, sin diferencias en terminos de gestacionmultiple, tasa de
aborto o EP. Doble ESI en fase lutea con Pipelle estuvo asociada con el mayor efecto sobre LBR (RR 1.54, 95% CI 1.10-2.16) y PR (RR
1.54, 95% CI 1.10-2.16). La ESI fue de beneﬁcio en mujeres con dos o mas fracasos en transferencias de embriones, pero no en mujeres
con un unico fracaso previo de transferencia embrionaria. No se encontro ningun efecto en mujeres sometidas a ciclos de transferencia
de embriones descongelados.
Conclusion (s): El ESI puede mejorar el exito de FIV, en mujeres con dos o mas fracasos previos en transferencias de embriones, some-
tidas a transferencias en fresco. El momento y tecnica de la ESI parecen jugar un papel fundamental en la determinacion de su efecto
sobre la implantacion embrionaria.
Palabras clave: Rascado endometrial, biopsia endometrial, momento de la lesion, infertilidad, fallo de implantacion.702 VOL. 110 NO. 4 / SEPTEMBER 2018
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